u HLA-B27 StripAssayConfirm early diagnosis of ankylosing spondylitis by HLA-B27 genotypingAnkylosing spondylitis, reactive arthritis and HLA-B27 allele The allelic variant HLA-B27 is well known as genetic risk factor for spondyloarthropathies, such as ankylosing spondylitis (AS), reactive arthritis, juvenile rheumatoid arthritis, and anterior uveitis. Ankylosing spondylitis, also known as Morbus Bechterew, is the most prevalent spondyloarthropathy affecting 0.1 - 1% of the general population. Up to 96% of patients with AS and up to 80% of patients with reactive arthritis carry the HLA-B27 allele. Patients suffer from chronic pain and stiffness in the back and pelvis and, with progressing disease, often develop spinal fusion. The disease usually manifests between 15-30 years of age and is three times more prevalent in males than in females. Often a time period of 5-10 years elapses between early, nonspecific symptoms and a definite diagnosis. Differentiating between HLA-B27 positive and negative patients is therefore an important parameter for diagnosing spondyloarthropathies. ViennaLab HLA-B27 StripAssay® detects disease-relevant HLA-B27 subtypes ^•1Simple protocol for complex diagnostic questions •| Manual or automated *1 No expensive lab equipment required *1 Ready-to-use reagents iA CE-labelled complete kit - DNA extraction included

ViennaLab HLA-B27 StripAssay® meets customer requirements Requirement ViennaLab’s offer i=rsjrsj/\/\5 ESTABLISHED INNOVATIONS IN DIAGNOSTICS Easy Three simple steps. 6 h. Done. Reliable Probes for HLA-B27 and control combined on one teststrip. Versatile Automated or manual processing. Incubator.Thermocycler. Shaker. That is all you need. Software for interpretation of results is optional. HLA-B27 StripAssay® • is based on reverse-hybridization of biotinylated PCR products • combines probes for HLA-B27 and control in a parallel array of allele-specific oligonucleotides • works with immobilized...